Protein– tag –
-
Akari Therapeutics and Whitehawk Therapeutics Partner on Trop2-Targeting ADC AKTX-101, Leveraging Novel PH1 Payload for Immune Activation
Markets Insider USA Overview Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics to advance its next-generation Antibody-Drug Conjugate (ADC) lead candidate, AKTX-101. AKTX-101 targets the Trop2 ... -
bioRxiv Reports Novel AR Molecular Glue Degrader GZL626 Inhibits Prostate Cancer Cell Proliferation, Effective Against AR-V7
bioRxiv USA Overview A preprint published on bioRxiv reports a novel androgen receptor (AR) molecular glue degrader, GZL626. GZL626 was shown to induce proteasome-dependent degradation of both full-length AR and the AR splicing variant A... -
FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%
Dana-Farber Cancer Institute USA Overview The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harborin... -
Nurix Therapeutics and Roche Secure HSR Clearance for Global Co-Development and Co-Commercialization Agreement of BTK Degrader Bexobrutideg
Nurix Therapeutics USA Overview Nurix Therapeutics announced HSR clearance for its global co-development and co-commercialization agreement with Roche for the BTK degrader bexobrutideg. Bexobrutideg is advancing in malignant hematology, ... -
NIH Launches ‘TRDNT Challenge’ to Drive Development of Precision RNA-Targeting Therapeutics for Disease
NIH USA Overview The National Institutes of Health (NIH) has initiated Phase I of the 'Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge' to foster a new class of RNA-targeting technologies. This initiative aims to accel... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
Antibody-Drug Conjugates Evolve into Smart Chemotherapy, Datroway Gains FDA Approval for Metastatic Triple-Negative Breast Cancer
Karchem Consulting USA Overview Antibody-Drug Conjugates (ADCs) are evolving into next-generation 'smart chemotherapies' by integrating precise targeting with innovative linker-payload technologies. Novel drug classes like nucleic acid a... -
First Oral ER PROTAC Vepdegestrant Gains FDA Approval, Ushering New Era in Targeted Protein Degradation
MDPI Switzerland Overview The field of Targeted Protein Degradation (TPD) marks a significant milestone with the FDA approval of vepdegestrant (VEPPANU, ARV-471), the first oral estrogen receptor (ER) targeted PROTAC, co-developed by Arv... -
CAD Blueprint-Guided Diffusion Achieves Precision Programming of Protein Shapes for Advanced Nanostructure Design
bioRxiv USA Overview A groundbreaking study introduces a novel method for precisely programming protein shapes using CAD blueprint-guided diffusion, enabling unprecedented control over nanoscale architectural design. This approach transi... -
mRNA-LNP Technology Proven Effective in COVID-19 Vaccines, Bolstering Drug Delivery Customization Capabilities
Inside Therapeutics USA Overview This article discusses the revolutionary potential of mRNA-lipid nanoparticles (LNPs) in pharmaceuticals, vaccines, and therapeutics. LNPs are highlighted as the most clinically advanced platform for mRNA...
